PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Paula Jacobs, Nat’l Cancer Institute to Speak at 6th Imaging Drug Discovery in May 8-10 in Boston, Massachusetts - Paula Jacobs, Associate Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute’s Cancer Imaging Program, to Speak at the 6th Imaging in Drug Discovery - GTCbio.com
Paula Jacobs, Nat’l Cancer Institute to Speak at 6th Imaging Drug Discovery in May 8-10 in Boston, Massachusetts

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2013/03/05 - Paula Jacobs, Associate Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute’s Cancer Imaging Program, to Speak at the 6th Imaging in Drug Discovery - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Paula Jacobs, Associate Director of Division of Cancer Treatment and Diagnosis at the National Cancer Institute’s Cancer Imaging Program, to speak on “Translational Molecular Imaging: Promises and Pitfalls” at GTC’s 6th Imaging in Drug Discovery and Development Conference (May 8-10, 2013 in Boston, MA)

Molecular imaging agents have great promise for investigating biology and for assisting in the development of new therapeutic drugs. However, many issues need to be addressed to reap the benefits. Developing imaging drugs is a difficult business model: imaging as an in vivo assay of molecular processes is challenging to standardize and validate and imaging in therapy development can founder with poor understanding of the therapeutic target or process. Funding to support trials can be difficult to find. Obtaining regulatory authorizations for clinical trials can be challenging, particularly when pairing an investigational molecular imaging probe with an investigational therapeutic drug. Imaging endpoints may or may not be acceptable to regulatory authorities for drug registration. This presentation will discuss the National Cancer Institute’s experience with non-proprietary investigational molecular probes in both imaging-only and imaging-therapy trial settings as well as a variety of regulatory strategies. A few unusual funding opportunities will be discussed.

Paula M. Jacobs, Ph.D. is the Associate Director in the Division of Cancer Therapeutics and Diagnostics at the National Cancer Institute, responsible for the Cancer Imaging Program. She came to work at the NCI after 30 years in the pharmaceutical and medical device industries, where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. Dr. Jacobs serves on three NCI Experimental Therapeutics (NExT) committees to review and manage the projects chosen for development. Her industrial experience includes roles at Clinical Assays, a division of Baxter Travenol; Seragen, a small biotechnology firm; and Advanced Magnetics. Dr. Jacobs received her undergraduate degree in chemistry at the Massachusetts Institute of Technology and graduate degrees at Tufts University and Northeastern University. Her post-doctoral training was at Northeastern University, Massachusetts Institute of Technology, and Peter Bent Brigham Hospital/Harvard Medical School. She has published in the areas of organic chemistry, inorganic chemistry, magnetic resonance imaging, neuro-oncology and nephrology.

GTC’s 6th Imaging in Drug Discovery and Development Conference brings together experts from academia, government, and industry from the National Cancer Institute, Stanford University, City of Hope and the Beckman Research Institute, Yale School of Medicine, Pfizer, Biogen Idec, PerkinElmer, Eisai, Columbia University, Roche, Sanofi, Janssen, and many more to discuss the most current developments and applications to further advance their molecular imaging projects on drug discovery and development.

This conference is also part of the Drug Discovery Summit 2013, which consists of this track and three other tracks:

7th Drug Design and Medicinal Chemistry
3rd Epigenetics in Drug Discovery
Orphan Drugs Research and Commercialization

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Paula Jacobs, Nat’l Cancer Institute to Speak at 6th Imaging Drug Discovery in May 8-10 in Boston, Massachusetts

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  Deb Sheppard - Medium Psychic Author Speaker





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)